daunoxome 2 mg/ml concentrate for solution for inf
galen limited - daunorubicin citrate - concentrate for susp for inf - 2 mg/ml
xylocaine 1.5% 375mg/25ml injection ampoule
astrazeneca pty ltd - lignocaine hydrochloride anhydrous -
mylotarg
pfizer europe ma eeig - gemtuzumab ozogamicin - leukemia, myeloid, acute - antineoplastic agents - mylotarg is indicated for combination therapy with daunorubicin (dnr) and cytarabine (arac) for the treatment of patients age 15 years and above with previously untreated, de novo cd33-positive acute myeloid leukaemia (aml), except acute promyelocytic leukaemia (apl).
zavedos cs 5mg5ml injection vials
pfizer (malaysia) sdn. bhd. - idarubicin hcl/demethoxy daunorubicin h* -
zavedos cs 10mg10ml injection vials
pfizer (malaysia) sdn. bhd. - idarubicin hcl/demethoxy daunorubicin h* -
zavedos cs 20mg20ml injection vials
pfizer (malaysia) sdn. bhd. - idarubicin hcl/demethoxy daunorubicin h* -
mylotarg
pfizer pharmaceuticals israel ltd - gemtuzumab ozogamicin - powder for concentrate for solution for infusion - gemtuzumab ozogamicin 5 mg/vial - gemtuzumab - mylotarg is indicated for the treatment of newly-diagnosed cd33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older.mylotarg is indicated for the treatment of relapsed or refractory cd33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older…….
daunobin 1 v. inj
oncomed - daunorubicin hcl. - inj - 20mg - 1 v.
daunocin v. inj
vhb - daunorubicin hcl. - inj - 20mg - v.
daunomycin 1 v. inj
pharmacia - daunorubicin hcl. - inj - 20mg - 1 v.